Calidi Biotherapeutics, Inc. Share-based Payment Arrangement, Expense
Calidi Biotherapeutics, Inc. (CLDI) reported Share-based Payment Arrangement, Expense of $157.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $157.00K, a 69.92% decline year-over-year.
- Calidi Biotherapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $231.00K, a 61.94% decline year-over-year.
- Calidi Biotherapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $450.00K, a 28.12% decline year-over-year.
- Calidi Biotherapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $529.00K, a 23.44% decline year-over-year.
- Calidi Biotherapeutics, Inc. share-based payment arrangement, expense for fiscal 2025 was $2.11M, a 28.71% decline from fiscal 2024.
- Calidi Biotherapeutics, Inc. share-based payment arrangement, expense for fiscal 2024 was $2.96M, a 38.51% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. share-based payment arrangement, expense for fiscal 2023 was $4.81M, a 6.35% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. share-based payment arrangement, expense for fiscal 2022 was $4.52M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $157.00K 10-Q · filed 2026-08-13 | $388.00K 10-Q · filed 2026-08-13 | $838.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.37M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $231.00K 10-Q · filed 2026-05-14 | $681.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.21M derived: sum of 3 quarters · filed 2026-05-14 | $1.73M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $979.00K derived: sum of 2 quarters · filed 2026-03-27 | $1.50M derived: sum of 3 quarters · filed 2026-08-13 | $2.11M 10-K · filed 2026-03-27 |
| 2025-09-30 | $529.00K 10-Q · filed 2025-11-13 | $1.05M derived: sum of 2 quarters · filed 2026-08-13 | $1.66M 10-Q · filed 2025-11-13 | $2.28M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $522.00K 10-Q · filed 2026-08-13 | $1.13M 10-Q · filed 2026-08-13 | $1.75M derived: sum of 3 quarters · filed 2026-08-13 | $2.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $607.00K 10-Q · filed 2026-05-14 | $1.23M derived: sum of 2 quarters · filed 2026-05-14 | $1.92M derived: sum of 3 quarters · filed 2026-05-14 | $2.67M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $626.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.32M derived: sum of 2 quarters · filed 2026-03-27 | $2.07M derived: sum of 3 quarters · filed 2026-03-27 | $2.96M 10-K · filed 2026-03-27 |
| 2024-09-30 | $691.00K 10-Q · filed 2025-11-13 | $1.44M derived: sum of 2 quarters · filed 2025-11-13 | $2.33M 10-Q · filed 2025-11-13 | $3.52M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $751.00K 10-Q · filed 2025-08-08 | $1.64M 10-Q · filed 2025-08-08 | $2.83M derived: sum of 3 quarters · filed 2025-08-08 | $3.93M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $888.00K 10-Q · filed 2025-05-14 | $2.07M derived: sum of 2 quarters · filed 2025-05-14 | $3.18M derived: sum of 3 quarters · filed 2025-05-14 | $4.26M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.29M derived: sum of 2 quarters · filed 2025-03-31 | $3.38M derived: sum of 3 quarters · filed 2025-03-31 | $4.81M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.11M 10-Q · filed 2024-11-12 | $2.19M derived: sum of 2 quarters · filed 2024-11-12 | $3.62M 10-Q · filed 2024-11-12 | $4.68M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.08M 10-Q · filed 2024-08-13 | $2.51M 10-Q · filed 2024-08-13 | $3.57M derived: sum of 3 quarters · filed 2024-08-13 | $4.63M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.43M 10-Q · filed 2024-05-14 | $2.49M derived: sum of 2 quarters · filed 2024-05-14 | $3.55M derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $2.12M derived: sum of 2 quarters · filed 2024-03-15 | $4.52M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $1.06M 10-Q · filed 2023-11-14 | $3.46M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |